Li Zhimin, He Guicheng, Zeng Hui, Wang Zhen, Yang Hui, Nai Aitao
Department of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Department of Ultrasound, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Transl Cancer Res. 2025 May 30;14(5):3017-3034. doi: 10.21037/tcr-2024-2362. Epub 2025 May 27.
Interleukin-11 receptor alpha () involves in numerous biological processes of malignant tumor. Nevertheless, the precise role of in lung adenocarcinoma (LUAD) remains unknown. This research aimed to elucidate the differential expression, methylation, prognosis significance and immune infiltration of in LUAD.
Using the University of Alabama at Birmingham Cancer Data Analysis Portal (UALCAN), The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), ONCOMINE, Gene Expression Profiling Interactive Analysis (GEPIA), and Human Protein Atlas (HPA) databases, the varied expression of in LUAD was confirmed. The level of methylation was investigated by UALCAN database. Spearman method was utilized to analyze the relevance between expression and its methylation. The prognostic significance of methylation was assessed using the Kaplan-Meier method. Furthermore, a meta-analysis based on TCGA and GEO databases was executed to judge the prognostic significance of in LUAD. Immune infiltration was evaluated by Gene set enrichment analysis (GSEA) analysis, single-sample gene set enrichment analysis (ssGSEA) analysis and Tumor Immune Estimation Resource (TIMER) database.
Our research demonstrated that expression was markedly diminished in LUAD. The low expression of was tightly linked with stage, T stage, N stage and cancer status. gene was inversely regulated by hypermethylation, resulting in its low expression in LUAD. The hypermethylation of implied poor prognosis in LUAD. Moreover, a meta-analysis of 2,964 LUAD patients from 23 studies demonstrated that low expression was positively associated with dismal overall survival (OS). Subsequently, we demonstrated that low expression of was closely linked to diverse immune cells, especially B cells.
Our work demonstrates that might be an underlying prognostic biomarker and an innovative molecular therapeutic target for individuals with LUAD.
白细胞介素-11受体α（IL11RA）参与恶性肿瘤的众多生物学过程。然而，IL11RA在肺腺癌（LUAD）中的具体作用仍不清楚。本研究旨在阐明IL11RA在LUAD中的差异表达、甲基化、预后意义及免疫浸润情况。
利用阿拉巴马大学伯明翰分校癌症数据分析门户（UALCAN）、癌症基因组图谱（TCGA）、基因表达综合数据库（GEO）、ONCOMINE、基因表达谱交互式分析（GEPIA）和人类蛋白质图谱（HPA）数据库，证实了IL11RA在LUAD中的表达差异。通过UALCAN数据库研究IL11RA的甲基化水平。采用Spearman法分析IL11RA表达与其甲基化之间的相关性。使用Kaplan-Meier法评估IL11RA甲基化的预后意义。此外，基于TCGA和GEO数据库进行荟萃分析，以判断IL11RA在LUAD中的预后意义。通过基因集富集分析（GSEA）分析、单样本基因集富集分析（ssGSEA）分析和肿瘤免疫估计资源（TIMER）数据库评估免疫浸润情况。
我们的研究表明，IL11RA在LUAD中表达明显降低。IL11RA的低表达与分期、T分期、N分期和癌症状态密切相关。IL11RA基因受高甲基化的反向调控，导致其在LUAD中低表达。IL11RA的高甲基化意味着LUAD预后不良。此外，对来自23项研究的2964例LUAD患者进行的荟萃分析表明，IL11RA低表达与总生存期（OS）不佳呈正相关。随后，我们证明IL11RA低表达与多种免疫细胞密切相关，尤其是B细胞。
我们的研究表明，IL11RA可能是LUAD患者潜在的预后生物标志物和创新的分子治疗靶点。
